With FDA approval for its breast cancer blockbuster hopeful, Celcuity…

The FDA has approved Celcuity's gedatolisib (Revtorpyk) for hormone receptor-positive, HER2-negative breast cancer, positioning it as a potential blockbuster with efficacy superior to competing agents and plans to expand into first-line use and prostate cancer indications. If you make companion diagnostics or biomarker tests for HR+/HER2- breast cancer, Revtorpyk's approval just created a new standard-of-care molecule that oncologists will now order tests to identify patients for. Your customer base expanded this week—call the labs and clinics using palbociclib-based regimens now.